| Name | Title | Contact Details |
|---|
The Faulkner Organization is a family-owned automotive dealership group based in Pennsylvania, founded in 1932. With a legacy of over nine decades, it operates 31 dealerships across Central and Southeastern Pennsylvania, representing 22 vehicle brands. The company specializes in the sale and service of new and pre-owned vehicles. Their offerings include automotive sales, maintenance and repair services, financing and insurance assistance, genuine parts supply, and body shop repair services. The Faulkner Organization is committed to customer satisfaction, employee development, and maintaining high ethical standards in all business dealings.
FM Global is a Rhode Island-based insurance company that specializes in property insurance, risk consulting and loss prevention for businesses.
Medical Claims Processing and Payer Solutions are Imagenets core business. Through our Paper to EDI, Adjudication, Claims Audit, and Contact Center solutions, Imagenet partners with each of our clients to ensure their compliance and business continuity needs are met, while helping implement bottom line efficiencies. All our solutions are Client Managed solutions, meaning your organization only supplies the business rules, and we respond with the tools, infrastructure, personnel, and subject matter experts, to accomplish the goals that your organization set out to accomplish. Our success is built upon our collaborative approach to engaging and delivering solutions to our trusted client partners. From our growing list of regional and locally staffed facilities, Imagenet performs as a natural extension of our client partners by delivering our solutions from local operating centers. Regional Facilities Located In: Arizona | California | Florida | Idaho | New Jersey | Pennsylvania | Texas | Washington
YA Group is an international professional services organization with over 25 years of experience, specializing in forensic consulting, engineering, and risk mitigation. Headquartered in the United States, the company employs more than 700 professionals and operates globally. It has evolved from its origins as a property damage consulting firm and has expanded through strategic acquisitions and organic growth. The firm offers a range of services, including forensic engineering and architecture, planning and construction advisory, and risk mitigation. Their expertise covers evaluations of existing structures, project controls, and comprehensive risk reduction strategies. YA Group serves a diverse clientele, including federal agencies, municipalities, healthcare systems, and educational institutions, emphasizing strong partnerships and a commitment to integrity and professionalism. The company is affiliated with several industry organizations, enhancing its credibility and expertise in the field.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.